KVUE 📈 Kenvue - Overview
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US49177J1025
KVUE: Health Supplements, Pain Relievers, Skincare Products, Baby Care Items
Kenvue Inc., a global consumer health company, operates through a diverse portfolio of segments, including Self Care, Skin Health and Beauty, and Essential Health, to provide a wide range of products that cater to various consumer needs. The Self Care segment is comprised of a broad array of products, such as cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other related items, which are marketed under well-established brand names like Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec. These brands are synonymous with trust and reliability, offering consumers effective solutions for managing everyday health issues.
The Skin Health and Beauty segment is another critical component of Kenvue Inc.'s business, focusing on the development and marketing of face and body care, hair, sun, and other care products. This segment boasts an impressive lineup of brands, including Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX, each with its unique value proposition and loyal customer base. By leveraging these brands, Kenvue Inc. is able to provide consumers with a comprehensive range of skin health and beauty solutions that cater to different needs and preferences.
The Essential Health segment rounds out Kenvue Inc.'s portfolio, offering a variety of oral and baby, women's health, wound, and other care products that are designed to promote overall health and well-being. This segment features a number of iconic brands, including Listerine, Johnson's, Band-Aid, and Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash, which have become household names over the years. By providing these essential products, Kenvue Inc. plays a vital role in supporting the health and hygiene needs of consumers around the world.
As a relatively new company, incorporated in 2022, Kenvue Inc. is headquartered in Skillman, New Jersey, and is listed on the New York Stock Exchange (NYSE) under the ticker symbol KVUE. With its common stock traded under the ISIN code US49177J1025, the company is classified within the Personal Care Products sub-industry, according to the Global Industry Classification Standard (GICS). For more information about Kenvue Inc., investors and consumers can visit the company's website at https://www.kenvue.com.
Additional Sources for KVUE Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
KVUE Stock Overview
Market Cap in USD | 43,790m |
Sector | Consumer Defensive |
Industry | Household & Personal Products |
GiC Sub-Industry | Personal Care Products |
IPO / Inception | 2023-05-04 |
KVUE Stock Ratings
Growth 5y | -29.2% |
Fundamental | 18.4% |
Dividend | 58.6% |
Rel. Strength Industry | -50.3 |
Analysts | 3.63/5 |
Fair Price Momentum | 20.95 USD |
Fair Price DCF | 18.91 USD |
KVUE Dividends
Dividend Yield 12m | 3.72% |
Yield on Cost 5y | 3.19% |
Annual Growth 5y | 42.30% |
Payout Consistency | 100.0% |
KVUE Growth Ratios
Growth Correlation 3m | 27.5% |
Growth Correlation 12m | 56.6% |
Growth Correlation 5y | -15% |
CAGR 5y | -8.93% |
CAGR/Mean DD 5y | -0.45 |
Sharpe Ratio 12m | 0.18 |
Alpha | -7.86 |
Beta | 0.44 |
Volatility | 29.19% |
Current Volume | 22915.1k |
Average Volume 20d | 13614.4k |
As of December 22, 2024, the stock is trading at USD 21.77 with a total of 22,915,123 shares traded.
Over the past week, the price has changed by -1.98%, over one month by -8.45%, over three months by -4.60% and over the past year by +8.06%.
Neither. Based on ValueRay Fundamental Analyses, Kenvue is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 18.41 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of KVUE as of December 2024 is 20.95. This means that KVUE is currently overvalued and has a potential downside of -3.77%.
Kenvue has received a consensus analysts rating of 3.63. Therefor, it is recommend to hold KVUE.
- Strong Buy: 4
- Buy: 2
- Hold: 10
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, KVUE Kenvue will be worth about 22.7 in December 2025. The stock is currently trading at 21.77. This means that the stock has a potential upside of +4.27%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 24.7 | 13.4% |
Analysts Target Price | 26.7 | 22.6% |
ValueRay Target Price | 22.7 | 4.3% |